Herantis Pharma initiates non-invasive CDNF development program, announces licensing agreement with University of Helsinki
Herantis Pharma initiates non-invasive CDNF development program, announces licensing agreement with University of Helsinki Herantis Pharma PlcCompany release 6 Jul 2018 at 9:00 am Herantis Pharma Plc ("Herantis") announced today the initiation of a non-invasive CDNF development program to broaden the application of CDNF in Parkinson's disease and potentially other neurodegenerative disorders. In conjunction, Herantis and the University of Helsinki have signed a licensing agreement granting Herantis worldwide, exclusive rights for the therapeutic application of a non-invasive CDNF